Cargando…
New Approach to Chronic Back Pain Treatment: A Case Control Study
Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855610/ https://www.ncbi.nlm.nih.gov/pubmed/36672581 http://dx.doi.org/10.3390/biomedicines11010073 |
_version_ | 1784873420088934400 |
---|---|
author | Bonetti, Matteo Lauritano, Dorina Ottaviani, Gian Maria Fontana, Alessandro Frigerio, Michele Zambello, Alessio Della Gatta, Luigi Muto, Mario Carinci, Francesco |
author_facet | Bonetti, Matteo Lauritano, Dorina Ottaviani, Gian Maria Fontana, Alessandro Frigerio, Michele Zambello, Alessio Della Gatta, Luigi Muto, Mario Carinci, Francesco |
author_sort | Bonetti, Matteo |
collection | PubMed |
description | Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations in a short (one week), medium (three months) and long-term period (six months). Methods: We enrolled 246 patients (Group A) with low back pain treated with periradicular infiltrations of oxygen-ozone under CT guide combined with 800 mg/day of ALA + 600 mg/day of PEA + 200 mg/day of myrrh orally. Group B consisted of 176 patients with low back pain treated with periradicular infiltrations of steroids. Patients were clinically monitored one week after the end of treatment, at three months, and at six months using a modified version of McNab’s method. Results: In Group A, the one-week clinical follow-up registered a complete remission of painful symptoms in 206 patients (83.7%), and this manifestation remained optimal in 191 patients at the three-month follow-up (77.6%) and in 178 at six months (72.3%). While the results were satisfactory in 28 patients (10.9%) at one week, 32 (13%) in the medium term, and 41 (16.6%) in the long term, non-significant results were found in 12 patients in the control at one week (4.6%), in 23 at three months (9.3%) and in 27 at six months (10.9%). In Group B, at the short-term follow-up we obtained an excellent clinical result in 103 patients (80.5%), while at three months 85 patients reported the persistence of clinical benefit (66.4%) and at six months, 72 (56.2%) reported the same result. The result was rated satisfactory in 11 (8.5%) and poor in 4 (3%). At the three-month follow-up, 23 (18%) reported a satisfactory result, and 20 (15.6%) had a poor result. At six months, 24 (18.8%) reported the persistence of a satisfactory result while for 32 the result was poor (25%). Conclusion: The results highlight how the treatment associated with ozone therapy and oral administration of alpha-lipoic acid + palmitoylethanolamide and myrrh can be considered a valid alternative to common therapeutic approaches in the treatment of chronic low back pain. |
format | Online Article Text |
id | pubmed-9855610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98556102023-01-21 New Approach to Chronic Back Pain Treatment: A Case Control Study Bonetti, Matteo Lauritano, Dorina Ottaviani, Gian Maria Fontana, Alessandro Frigerio, Michele Zambello, Alessio Della Gatta, Luigi Muto, Mario Carinci, Francesco Biomedicines Article Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations in a short (one week), medium (three months) and long-term period (six months). Methods: We enrolled 246 patients (Group A) with low back pain treated with periradicular infiltrations of oxygen-ozone under CT guide combined with 800 mg/day of ALA + 600 mg/day of PEA + 200 mg/day of myrrh orally. Group B consisted of 176 patients with low back pain treated with periradicular infiltrations of steroids. Patients were clinically monitored one week after the end of treatment, at three months, and at six months using a modified version of McNab’s method. Results: In Group A, the one-week clinical follow-up registered a complete remission of painful symptoms in 206 patients (83.7%), and this manifestation remained optimal in 191 patients at the three-month follow-up (77.6%) and in 178 at six months (72.3%). While the results were satisfactory in 28 patients (10.9%) at one week, 32 (13%) in the medium term, and 41 (16.6%) in the long term, non-significant results were found in 12 patients in the control at one week (4.6%), in 23 at three months (9.3%) and in 27 at six months (10.9%). In Group B, at the short-term follow-up we obtained an excellent clinical result in 103 patients (80.5%), while at three months 85 patients reported the persistence of clinical benefit (66.4%) and at six months, 72 (56.2%) reported the same result. The result was rated satisfactory in 11 (8.5%) and poor in 4 (3%). At the three-month follow-up, 23 (18%) reported a satisfactory result, and 20 (15.6%) had a poor result. At six months, 24 (18.8%) reported the persistence of a satisfactory result while for 32 the result was poor (25%). Conclusion: The results highlight how the treatment associated with ozone therapy and oral administration of alpha-lipoic acid + palmitoylethanolamide and myrrh can be considered a valid alternative to common therapeutic approaches in the treatment of chronic low back pain. MDPI 2022-12-28 /pmc/articles/PMC9855610/ /pubmed/36672581 http://dx.doi.org/10.3390/biomedicines11010073 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bonetti, Matteo Lauritano, Dorina Ottaviani, Gian Maria Fontana, Alessandro Frigerio, Michele Zambello, Alessio Della Gatta, Luigi Muto, Mario Carinci, Francesco New Approach to Chronic Back Pain Treatment: A Case Control Study |
title | New Approach to Chronic Back Pain Treatment: A Case Control Study |
title_full | New Approach to Chronic Back Pain Treatment: A Case Control Study |
title_fullStr | New Approach to Chronic Back Pain Treatment: A Case Control Study |
title_full_unstemmed | New Approach to Chronic Back Pain Treatment: A Case Control Study |
title_short | New Approach to Chronic Back Pain Treatment: A Case Control Study |
title_sort | new approach to chronic back pain treatment: a case control study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855610/ https://www.ncbi.nlm.nih.gov/pubmed/36672581 http://dx.doi.org/10.3390/biomedicines11010073 |
work_keys_str_mv | AT bonettimatteo newapproachtochronicbackpaintreatmentacasecontrolstudy AT lauritanodorina newapproachtochronicbackpaintreatmentacasecontrolstudy AT ottavianigianmaria newapproachtochronicbackpaintreatmentacasecontrolstudy AT fontanaalessandro newapproachtochronicbackpaintreatmentacasecontrolstudy AT frigeriomichele newapproachtochronicbackpaintreatmentacasecontrolstudy AT zambelloalessio newapproachtochronicbackpaintreatmentacasecontrolstudy AT dellagattaluigi newapproachtochronicbackpaintreatmentacasecontrolstudy AT mutomario newapproachtochronicbackpaintreatmentacasecontrolstudy AT carincifrancesco newapproachtochronicbackpaintreatmentacasecontrolstudy |